IRB Number: 2015-184
inactive
June 16, 2017
Institutional Review Board, Hospital for Special Surgery
The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial or research study, the investigator will explain the purpose of the trial/study, its expected benefits, any possible risks or side effects, and what your role will be. If you want to join the trial/study, you must sign informed consent documents. You can leave a trial/study at any time without penalty.
For further information, see Understanding Clinical Trials/Research Studies.
Principal Investigator
Peter J. Moley, MD
Co-Investigators
James F. Wyss, MD, PT
Gregory Lutz, MD
Jonathan Kirschner, MD
Eric Holder, MD
Jessica Hettler, PT
Jennifer Cheng, PhD
Summary
Gluteus medius tendinopathy, which is often referred to as Greater Trochanteric Pain Syndrome, is characterized by pain in the lateral aspect of the hip that is aggravated by side lying, stair climbing, and walking. Treatment is currently limited to lifestyle modifications, corticosteroid injections, physical therapy, and open and endoscopic surgical repair. Platelet-rich plasma (PRP) injections contain important growth factors that are essential in the healing and tissue formation processes. However, the extent to which PRP is more efficacious than whole blood in tendinopathy remains unclear. In this double-blind randomized trial, patients will be allocated to receive an injection of either PRP or whole blood. Post-procedure assessments will occur at 6 weeks, 3 months, 6 months, 9 months, and 1 year. Study-specific physical therapy sessions will occur at 2 weeks and 6-8 weeks post-procedure.
Inclusion/Exclusion Criteria
Gluteus medius tendinopathy, which is often referred to as Greater Trochanteric Pain Syndrome, is characterized by pain in the lateral aspect of the hip that is aggravated by side lying, stair climbing, and walking. Treatment is currently limited to lifestyle modifications, corticosteroid injections, physical therapy, and open and endoscopic surgical repair. Platelet-rich plasma (PRP) injections contain important growth factors that are essential in the healing and tissue formation processes. However, the extent to which PRP is more efficacious than whole blood in tendinopathy remains unclear. In this double-blind randomized trial, patients will be allocated to receive an injection of either PRP or whole blood. Post-procedure assessments will occur at 6 weeks, 3 months, 6 months, 9 months, and 1 year. Study-specific physical therapy sessions will occur at 2 weeks and 6-8 weeks post-procedure.
Contact Information
Jennifer Cheng
chengj@hss.edu
646.714.6870
Nicole Hurwitz
hurwitzn@hss.edu
212.774.7386